Advertisement
U.S. markets open in 7 hours 55 minutes

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0000-0.2100 (-4.99%)
At close: 04:00PM EDT

Alimera Sciences, Inc.

6310 Town Square
Suite 400
Alpharetta, GA 30005
United States
678 990 5740
https://alimerasciences.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees154

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard S. Eiswirth Jr.CEO & Director597.87kN/A1968
Mr. David R. HollandCo-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets413.5kN/A1964
Dr. Philip Ashman Ph.D.President of International Operations389.86kN/A1965
Mr. Todd Michael WoodPresident of U.S. OperationsN/AN/A1970
Mr. Elliot Maltz CPACFO & TreasurerN/AN/A1985
Mr. Jason WernerChief Operating OfficerN/AN/AN/A
Christopher S. VisickVP, General Counsel & SecretaryN/AN/AN/A
Dr. David Dyer M.D.Chief Retina SpecialistN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Alimera Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.